Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07
Daniel Helbling(University Hospital of Bern), Dieter Koeberle(Kantonsspital St. Gallen), Stéphanie Bougel(University of Lausanne), Roger Burkhard(GastroZentrum Hirslanden Zürich), Beat Gloor(University of Bern), G. Bodoky(Unified Szent István and Szent László Hospital), Daniela Baertschi(Swiss Group For Clinical Cancer Research), Jean Benhattar(University of Lausanne), Elisabeth Oppliger Leibundgut(University Hospital of Bern), Piercarlo Saletti(Institute of Oncology Research), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Lukas Werner Widmer(GastroZentrum Hirslanden Zürich), Fred T. Bosman(Leiden University Medical Center), Axel Madlung, Ping Yan(University of Lausanne), Hong Sun(Swiss Group For Clinical Cancer Research), Daniel Rauch(Washington University in St. Louis), Markus Borner(University of Bern), Sun Young Rha(Yonsei University)
Cited by 86
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
|Annals of Oncology|2019|1.4k
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|838
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835